Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Toronto
$27,000.00
Defining MAP17’s role in PDZK1–SR-B1 Signalling and Cholesterol Homeostasis
EF 2025-26
Résumé
Cholesterol regulation is critical for maintaining cardiovascular health. High-density lipoproteins (HDL), or good cholesterol, protect against atherosclerosis by transporting excess cholesterol out of peripheral tissues. This prevents the formation of fatty plaques that narrow arteries and lead to heart attack or stroke. My project focuses on the molecular steps by which HDL interacts with liver cells which is the central site of cholesterol clearance, and the proteins that enable these cells to take up and process cholesterol efficiently.
A central player in this process is the HDL receptor SR-B1, which extracts cholesterol from HDL particles. SR-B1 depends on the adaptor protein PDZK1 for its stability and proper function at the cell membrane. A smaller protein, MAP17, has been shown to reduce PDZK1 levels, but its role in cholesterol uptake and the mechanism by which it affects PDZK1 remains unclear. Uncovering how MAP17 fits into this pathway could reveal an overlooked regulatory step in HDL-mediated cholesterol transport.
To investigate this, I will manipulate MAP17 expression using overexpression constructs, targeted mutants, and knockdown approaches, then measure the resulting effects on SR-B1 and PDZK1 protein levels, localization, and cholesterol uptake. I will also test whether MAP17 variants physically associate with PDZK1 or SR-B1, providing insight into how it may influence HDL-responsive signalling pathways.
By examining MAP17 as a potential downstream regulator of SR-B1, this work aims to broaden our understanding of how HDL protects against atherosclerosis at the cellular level. Identifying new molecular players in HDL and LDL uptake may ultimately guide the development of novel therapeutic strategies to reduce cardiovascular disease risk.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
573160
Name
Shao Chu ting
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Defining MAP17’s role in PDZK1–SR-B1 Signalling and Cholesterol Homeostasis
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cholesterol Homeostasis; Cloning; Hdl Uptake; Hepatic Lipid Regulation; Map17 (Pdzk1ip1); Membrane Proteins; Pdzk1; Protein Interactions; Reverse Cholesterol Transport; Sr-B1
Abstract
Cholesterol regulation is critical for maintaining cardiovascular health. High-density lipoproteins (HDL), or good cholesterol, protect against atherosclerosis by transporting excess cholesterol out of peripheral tissues. This prevents the formation of fatty plaques that narrow arteries and lead to heart attack or stroke. My project focuses on the molecular steps by which HDL interacts with liver cells which is the central site of cholesterol clearance, and the proteins that enable these cells to take up and process cholesterol efficiently.
A central player in this process is the HDL receptor SR-B1, which extracts cholesterol from HDL particles. SR-B1 depends on the adaptor protein PDZK1 for its stability and proper function at the cell membrane. A smaller protein, MAP17, has been shown to reduce PDZK1 levels, but its role in cholesterol uptake and the mechanism by which it affects PDZK1 remains unclear. Uncovering how MAP17 fits into this pathway could reveal an overlooked regulatory step in HDL-mediated cholesterol transport.
To investigate this, I will manipulate MAP17 expression using overexpression constructs, targeted mutants, and knockdown approaches, then measure the resulting effects on SR-B1 and PDZK1 protein levels, localization, and cholesterol uptake. I will also test whether MAP17 variants physically associate with PDZK1 or SR-B1, providing insight into how it may influence HDL-responsive signalling pathways.
By examining MAP17 as a potential downstream regulator of SR-B1, this work aims to broaden our understanding of how HDL protects against atherosclerosis at the cellular level. Identifying new molecular players in HDL and LDL uptake may ultimately guide the development of novel therapeutic strategies to reduce cardiovascular disease risk.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shao, Chu ting
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~